XORTX Therapeutics Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for XRTX, updated each market day.
XRTX AI Sentiment
AI predicts XORTX Therapeutics Inc. Common Stock stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About XORTX Therapeutics Inc. Common Stock
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
Exchange
Market Cap
$3,181,734
Cap Tier
Employees
3
Listed Since
May 4, 2018
Website
XRTX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
XRTX Volatility
XORTX Therapeutics Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
